Study of the antiviral action of the abnormal nucleoside analogue 2-(beta-Dribofuranosyl)-5-amino-1,2,4-triazine-3(2H)-one was performed with Epstein-Barr virus (EBV) positive human B-cells (Raji) superinfected by EBV, as an acute infection model, and EBV-producing tamarin (Saguinus oedipus) B-cell line (B95-8), as a chronic infection model. The antiviral activity of the compound was determined by RT-PCR. It was shown that the IC 50 values (concentration of compound that inhibits the accumulation of the viral genome at 50 %) for 2-(beta-D-ribofuranosyl-5-amino-1,2,4-triazine-3(2H)-one were 0.5 ug/ml for the acute infection of EBV infected Raji cells and 0.76 ug/ml for the model of chronic infection. The anti-EBV action of Ganciclovir (the official anti-herpetic drug) was studied for comparison. IC 50 values for Ganciclovir were 1.3 ug/ml for the acute model and below 0.5 ug/ml for the chronic model of EBV infections. Thus abnormal nucleoside 2-(beta-D-ribofuranosyl)-5-amino-1,2,4-triazine-3(2H)-one is a promising anti-EBV compound deserving further research.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.